Each year, more than two million patients worldwide undergo a procedure called coronary artery bypass grafting (CABG). CABG is used to treat blocked arteries and restore normal blood flow to the heart. It involves grafting a blood vessel — typically taken from the leg — around the diseased area, reestablishing blood flow to the heart tissue. However, veins used for CABG offer an inadequately durable solution to coronary artery disease, and the long-term outlook is not promising. Within 18 months, 25 percent of implanted veins fail. After 5 years, that failure rate increases to 40 percent. Angioshield, a novel type of external stent designed through ANSYS' computer simulations, offers a solution to this problem.
Each year, more than two million patients worldwide undergo a procedure called coronary artery bypass grafting (CABG). CABG is used to treat blocked arteries and restore normal blood flow to the heart. It involves grafting a blood vessel — typically taken from the leg — around the diseased area, reestablishing blood flow to the heart tissue. However, veins used for CABG offer an inadequately durable solution to coronary artery disease, and the long-term outlook is not promising. Within 18 months, 25 percent of implanted veins fail. After 5 years, that failure rate increases to 40 percent. Angioshield, a novel type of external stent designed through ANSYS' computer simulations, offers a solution to this problem.